Johnson & Johnson (VIE:JNJ)
Austria · Delayed Price · Currency is EUR | Market Cap | 467.80B +42.1% |
| Revenue (ttm) | 83.64B +7.9% |
| Net Income | 18.26B -3.5% |
| EPS | 7.50 -3.9% |
| Shares Out | n/a |
| PE Ratio | 25.61 |
| Forward PE | 19.08 |
| Dividend | 4.49 (2.31%) |
| Ex-Dividend Date | Feb 24, 2026 |
| Volume | 158 |
| Average Volume | 47 |
| Open | 194.06 |
| Previous Close | 194.46 |
| Day's Range | 192.10 - 194.06 |
| 52-Week Range | 129.40 - 214.30 |
| Beta | n/a |
| RSI | 37.59 |
| Earnings Date | Apr 14, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
J&J sees AI halving the time to generate drug development leads
Johnson & Johnson is using artificial intelligence to slash by half the time it takes to generate new leads for developing drugs, the company's chief information officer said on Monday.
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in w...
Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports
Johnson & Johnson will start marketing four of its medications on the Trump administration's TrumpRx website on Friday, CBS News reported on Friday.
Cramer says look to these 4 stocks to go with your high-flying tech names
CNBC's Jim Cramer urged investors to look at parts of the market that have already been beaten down. He highlighted four stocks in the health-care sector as alternatives to high-flying technology and ...
Johnson & Johnson Transcript: AGM 2026
Strong financial growth in 2025 included a 43% share price increase and record pharmaceutical sales. All board nominees and management proposals passed, while a shareholder proposal was rejected. Strategic focus remains on innovation, portfolio strength, and disciplined capital allocation.
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving ...
Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson announces that it has received European CE Mark approval for its new ETHICON™ 4000 Stapler.
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th. Management will participate in a...
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson showcases CARTO-powered innovation, including debut of CARTOSOUND SONATA, to advance arrhythmia care at HRS 2026.
US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims
A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer in hal...
U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims
A federal judge rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer i...
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bank of America 2026 Healthcare Conference on Tuesday, May 12th, 2026. Management will participate in a Fireside...
These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results
Johnson & Johnson (NYSE: JNJ) on Tuesday posted upbeat earnings for the first quarter.
Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst
• Johnson & Johnson stock is trending lower. Why is JNJ stock trading lower?
Johnson & Johnson CFO on the company's robotic surgical system
Johnson & Johnson CFO Joseph Wolk discusses the company's latest FDA application for its OTTAVA robotic surgical system.
Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings
Oracle's (ORCL) rebound rally continues after extending a partnership with Bloom energy (BE). Diane King Hall explains why the headline offers a bullish catalyst for both companies.
Johnson & Johnson Earnings Call Transcript: Q1 2026
Q1 2026 saw 6.4% operational sales growth, strong performance across all segments, and raised full-year guidance. Key brands and new launches drove double-digit growth in Innovative Medicine, while MedTech and Vision showed solid momentum. Dividend increased for the 64th consecutive year.
J&J raises guidance for 2026 on strong start to the year
The healthcare giant saw sales of medications, which include Darzalex and Tremfya, increase 11% in the first three months of the year
J&J's first-quarter profit beats estimates even as Stelara sales disappoint
Johnson & Johnson reported first-quarter earnings that beat Wall Street expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment T...
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 pe...
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2026. “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a...
J&J's First-Quarter Sales Grow on Cancer-Drug Strength
The drug and medical-device giant has been working to ensure consistent growth after losing patent protection for its blockbuster Stelara.
Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports
The Dow Jones Industrial Average enters the week in the spotlight with four of the 30 component stocks set to report quarterly earnings results this week.
Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week
Big Banks kick off first-quarter earnings, but we'll also hear from Abbot Labs, PepsiCo, ASML, and more. And we'll see economic data on producer prices, housing, and the mood among small businesses.